Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroVax plus first-line standard of care in advanced or metastatic clear cell renal cell carcinoma
2006-001246-13Phase 3Completed
- Sponsor
- Oxford BioMedica
- Start
- Jul 2006
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in clear cell renal cell carcinoma (ccRCC) comparing TroVax + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Overall survival. Started Jul 2006; status: completed.
02
Drugs
MVA-5T4
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2006-001246-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001246-13.